Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression … (NCT03999710) | Clinical Trial Compass
Active — Not RecruitingPhase 2
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
United States61 participantsStarted 2019-07-19
Plain-language summary
The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. Patients with vitiligo or alopecia
. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
. Any chronic skin condition that does not require systemic therapy
. Patients without active disease in the last 5 years may be included but only after consultation with the study physician
. Patients with celiac disease controlled by diet alone
. Patients with Grade \>/= neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician
. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This is a Phase 2 trial combining durvalumab with radiation therapy for Stage II or III non-small cell lung cancer — does the fact that it's still Phase 2 mean there are unknowns about safety or long-term benefit that I should weigh against standard treatment options?
2The trial is measuring whether patients are progression-free at 2 years — based on what's been seen so far, how does that goal compare to what I might expect from the standard treatment approach for my stage of NSCLC?
3Since the trial is no longer enrolling new patients, is there any way for me to access durvalumab combined with radiation outside of this study, or is a similar combination already available to me as a standard or approved option?
4Durvalumab is an immunotherapy drug — given my specific health history, are there any immune-related side effects I should be especially concerned about if this type of combination were considered for my care?
5For Stage II or III NSCLC like mine, would my doctor recommend trying standard treatment first, or is there a reason why participating in or following the results of a trial like this one might change the approach we take?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. Treatment with a monoclonal antibody within 4 weeks prior to study Day 1 or has not recovered (i.e., \>/= Grade 1 at baseline) from adverse events due to agents administered \> 4 weeks earlier (intraocular bevacizumab is acceptable)